Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Live Attenuated, Dried, TC-83, NDBR 102, Lot 4, Run 3, as Primary Vaccination in Healthy Adult Subjects at Risk of Exposure to VEE Virus

NCT03051386 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.

NCT NCT03051386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03051386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Live Attenuated, Dried, TC-83, NDBR 102, Lot 4, Run 3, as Primary Vaccination in Healthy Adult Subjects at Risk of Exposure to VEE Virus
Lead sponsor
U.S. Army Medical Research and Development Command
Phase
Phase 2
Overall status
Unknown status
Start date
May 30, 2018
Completion date
April 1, 2023
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

venezuelan equine encephalomyelitis virus disease